Picture of Sanofi SA logo

SAN — Sanofi SA Share Price

0.000.00%
fr flag iconLast trade - 00:00
HealthcareConservativeLarge CapNeutral

Momentum

Relative Strength (%)
1m+1.88%
3m+5.14%
6m-0.83%
1yr-5.92%
Volume Change (%)
10d/3m-1.87%
Price vs... (%)
52w High-0.58%
50d MA+4.81%
200d MA+6.16%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)12.82
PEG Ratio (f)1.25
EPS Growth (f)11.39%
Dividend Yield (f)3.81%
Valuation (ttm)IndustryMarket
Price to Book Value1.82
Price to Tang. Bookn/a
Price to Free Cashflow19.79
Price to Sales3.06
EV to EBITDA11.55

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital9.35%
Return on Equity10.52%
Operating Margin23.14%

Financial Summary

Year End 31st DecUnit201620172018201920202021E2022ECAGR / Avg
Total Revenue€m34,69636,22135,67737,63137,36938,389.4340,579.351.4%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%-11.43-6.36+27.3+13.95+95.45-37.68+11.39n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for SAN

Here is how city analysts rate Sanofi Sa background image

Here is how city analysts rate Sanofi Sa

When it comes to researching shares, many investors take note of what city analysts have to say. The trading recommendations of these professionals are used by everyone from institutional fund managers to individual private investors....

Here is what expert analysts think about Sanofi Sa background image

Here is what expert analysts think about Sanofi Sa

City analysts understand the companies they cover better than anyone - so it can pay to take note of their trading recommendations. 'Buy', 'hold' and 'sell' ratings can be a useful signal when it comes to deciding whether to buy a shar...

Why Sanofi Sa passes three vital dividend tests background image

Why Sanofi Sa passes three vital dividend tests

In times of great uncertainty, stocks with solid yields and track records of consistent and well-financed dividend growth are like gold dust. For investors right across the market-cap range, decent dividends are a pointer to potentiall...

Upbeat broker recommendations for Sanofi Sa background image

Upbeat broker recommendations for Sanofi Sa

The Sanofi Sa (EPA:SAN) share price has risen by 5.34% over the past month and it’s currently trading at 82.47. For investors considering whether to buy, hold or sell the stock, the question now is whether this price run will continue....

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of Sanofi SA EPS forecast chart

Profile Summary

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.

Directors

Last Annual
December 31st, 2020
Last Interim
September 30th, 2021
Incorporated
May 11th, 1994
Public Since
July 1st, 2002
No. of Employees
99,412
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
fr flag iconEuronext - Paris
Shares in Issue
1,252,535,780

SAN Share Price Performance

Latest News for SAN

Upcoming Events for SAN

Q4 2021 Sanofi SA Earnings Release

Q4 2021 Sanofi SA Earnings Call

Q1 2022 Sanofi SA Earnings Release

Q1 2022 Sanofi SA Earnings Call

Sanofi SA Annual Shareholders Meeting

Similar to SAN

Picture of AB Science SA logo

AB Science SA

fr flag iconEuronext - Paris

Picture of Advicenne SA logo

Advicenne SA

fr flag iconEuronext - Paris

Picture of Biocorp Production SA logo

Biocorp Production SA

fr flag iconEuronext - Paris

Picture of Boiron SA logo

Boiron SA

fr flag iconEuronext - Paris

Picture of DBV Technologies SA logo

DBV Technologies SA

fr flag iconEuronext - Paris

FAQ

Or unlock with your email

Or unlock with your email